Vernalis: Notice of Interim Financial Results
23 August 2006
Vernalis plc (LSE: VER, Nasdaq: VNLS) today announces that it will be releasing its interim results for the six months ended 30 June 2006 on Tuesday, 12 September 2006.
An analyst briefing will be held at 9.00 a.m. on 12 September at The Royal College of Surgeons, 35-43 Lincoln's Inn Fields, London. WC2A 3PE.
-- ends --
Enquiries:
Vernalis plc +44 (0) 118 977 3133
Simon Sturge, Chief Executive Officer
Tony Weir, Chief Financial Officer
Julia Wilson, Head of Corporate Communication
Brunswick Group +44 (0) 20 7404 5959
Jon Coles
Justine McIlroy
About Vernalis
Vernalis is a speciality bio-pharmaceutical company focused on products marketed to specialist neurologists. The company has two marketed products, Frova® and Apokyn®, and a development pipeline focused on neurology and central nervous system disorders. The company has seven products in clinical development and collaborations with leading, global pharmaceutical companies including Novartis, Biogen Idec, Serono and Chiesi. Vernalis has established a US commercial operation to promote Apokyn® and co-promote Frova® alongside its North American licensing partner, Endo Pharmaceuticals, propelling the company towards its goal of becoming a sustainable, self-funding, R&D-driven, speciality bio-pharmaceutical company. For further information about Vernalis, please visit www.vernalis.com.
